Although RAF and MEK inhibitors are increasingly applied for refractory histiocytosis [14], reported toxicities [15, 16] in patients provide a rationale to choose RT above systemic therapy in selected cases. This evidence concerns the gene MAP2K7 and Histiocytosis.